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MutagenesisThe envelope glycoprotein (GP) of Ebolavirus (EBOV) mediates viral entry into host cells. Through
mutagenesis, we and other groups reported that two phenylalanines at positions 88 and 159 of GP are critical
for viral entry. However, it remains elusive which steps of viral entry are impaired by F88 or F159 mutations
and how. In this study, we further characterized these two phenylalanines throughmutagenesis and examined
the impact on GP expression, function, and structure. Our data suggest that F159 plays an indirect role in viral
entry by maintaining EBOV GP's overall structure. In contrast, we did not detect any evidence for
conformational differences in GP with F88 mutations. The data suggest that F88 inﬂuences viral entry during
a step after cathepsin processing, presumably impacting viral fusion.
Published by Elsevier Inc.Introduction
Ebolavirus (EBOV) infection causes Ebola hemorrhagic fever with
mortality rates up to 90%. The genus Ebolavirus belongs to the family
Filoviridae and is composed of ﬁve species: Zaire, Sudan, Ivory Coast,
Bundibugyo, and Reston (Gonzalez et al., 2007; Towner et al., 2008).
There are no approved therapies or vaccines, although promising pre-
clinical studies have been reported for some Ebolavirus vaccines (Reed
and Mohamadzadeh, 2007).
EBOV is an enveloped negative strand RNA virus. The envelope
glycoprotein (GP) is ﬁrst synthesized as a precursor (GP0), which is
subsequently cleaved by furin into the surface glycoprotein (GP1,
aa1–501) and the transmembrane glycoprotein (GP2, aa502–676)
(Volchkov et al., 1998). GP1 and GP2 are linked together through a
disulﬁde bond (Jeffers et al., 2002). GP1 contains the receptor binding
domain (amino acids 54–201), and GP2 contains the membrane
fusion machinery that induces viral and endosomal membrane fusion
resulting in release from the endosomes (Chandran et al., 2005; Kuhn
et al., 2006; Schornberg et al., 2006; Takada et al., 1997; Volchkov et
al., 1998; Wool-Lewis and Bates, 1998). Though the receptor for EBOV
remains elusive, several host factors that can aid virus infection have
been reported (Alvarez et al., 2002; Chan et al., 2001; Powlesland et
al., 2008; Shimojima et al., 2006; Simmons et al., 2003a, 2003b;
Takada et al., 2004). Following the binding of GP1 to EBOV receptor,ilson).
ogram, University of Maryland,
Inc.pseudovirions bearing EBOV GP have been shown to undergo
endocytosis and GP1 is further processed in endosomes by cathepsin
L and/or cathepsin B to generate a fragment of approximately 19 kDa,
which remains linked to GP2 through a disulﬁde bond. Cathepsin
processing is currently thought to prime EBOV GP for fusion, which
may play a direct or indirect role in exposing the membrane fusion
machinery in GP2 (Chandran et al., 2005; Schornberg et al., 2006).
We and others have shown that phenylalanines 88 and 159 in GP1
play important roles in EBOV GP-mediated viral entry (Brindley et al.,
2007; Manicassamy et al., 2005; Mpanju et al., 2006). However, it
remains unclear which step of viral entry is impaired by mutation of
F88 or F159. According to the recently reported GP crystal structure,
F88 is partially exposed on the GP1 surface adjacent to the putative
receptor binding site and the GP2 internal fusion loop, while F159 is
deeply buried within a hydrophobic pocket (Lee et al., 2008) (Fig. 1).
Both of these residues are surrounded by a group of hydrophobic
amino acids (Fig. 1). The properties of an amino acid are determined by
its side chains, including size, shape, charge, polarity, and hydropho-
bicity. To gain further understanding of how these two phenylalanines
affect EBOVGP structure and function,wemutated eachphenylalanine
to either histidine, valine or tyrosine, and characterized eachmutation
for its impact on GP's structure and function.Results
Impact of F88 and F159 mutations on EBOV GP-mediated infection
To gain a better understanding on how F88 and F159 contribute to
EBOV GP's structure and function, we further mutated F88 to histidine
Fig. 1. Crystal structure of EBOVGPΔMucΔTM. (A) Ribbon diagram of EBOVGPΔMucΔTM trimerwith onemonomer in yellow, another one in green and the third one in red. F88 (purple)
and F158 (blue)arehighlighted. (B) Filledmodel structure of amonomer. F88 (purple) ispartially exposedwhile F159 (darkblue) isdeeplyburied. (C)Ribbondiagramshowing thevicinity
of F88 to GP2 internal fusion loop (brown). GP1 is shown in light grey, and GP2 in dark grey. (D) Filledmodel showing the vicinity of F88 to residues that are labeled and suggested to be
important for binding to EBOV receptor (based on Dube et al., 2009). (E and F) Ribbon diagrams showing amino acids adjacent to F88 and F159, respectively. Both F88 and F159 are
surrounded by a group of hydrophobic amino acids. The graphic structure was produced using Pymol and PDB ﬁle 3CSY and is based on the published crystal structure (Lee et al., 2008).
Fig. 2. Infectivity of EBOV GP mutants. HeLa cells were infected with MLV(GP)
pseudovirus and histochemically stained for β-galactosidase activity 48 h after
infection. Virus titer was determined by counting the blue forming units (BFU) and
used to calculate the relative infectivity by normalizing all values to the infectivity titers
observed for MLV(WT GP) pseudovirions. The absolute titer for theWTwas 2230±122
BFU. In these experiments, mock represents cells exposed to supernatant collected from
cells exposed to transfection reagents only in the absence of any DNA.
136 W. Ou et al. / Virology 396 (2010) 135–142(H), valine (V), or tyrosine (Y), generated MLV(GP) retroviral vector
pseudotypes bearing WT or mutant GP, and tested their infectivity on
HeLa cells. We found the infectivity titers of F88H, F88V, and F88Y
were about 0.3%, 66%, and 93% that of the WT, respectively (Fig. 2).
The titer for vectors bearing WT GP was 2230±122 BFU. We also
mutated F159 to H, V, or Y, and found the infectivity titers of the MLV
(GP) mutants were about 0%, 28%, and 25% of vectors bearing WT GP,
respectively (Fig. 2). As we reported previously (Mpanju et al., 2006),
retroviral vector pseudotypes carrying GP with F88A or F159A
mutations were non-infectious (Fig. 2).
Impact of F88 and F159 mutations on GP expression or incorporation
To determine whether the decrease in infectivity titer was due to a
decrease in GP expression or incorporation into the virions, we checked
GP expression level in the total lysate, on the cell surface, or on
pseudovirions byWestern blot. All themutant GPswerewell expressed
though their expression level varied slightly (Fig. 3A). The same
membrane was stripped and re-blotted with anti-beta actin antibody
to conﬁrm that the sample loadingwaseven (Fig. 3B). The cell surfaceGP
level, which should have a direct impact on GP incorporation level on
virus particles andhence the titer, did not correlatewith the titer, in that
cell surface GP was detected even in mutants that had very low or no
detectable infectious titer, such as F88H and F159H, suggesting that lack
of GP incorporation is not responsible for the poorly infectious
phenotype of these mutants (Fig. 3C). Again, the sample loadingwas conﬁrmed to be even (Fig. 3D). Western blot analysis of the
virus-containing crude supernatant also showed comparable levels of
GP with only slight variations in GP level that did not correlate with the
pseudovirus titer (Fig. 3E).
Fig. 3.Western blot detection of EBOV GP. 293T cells were transfected to produce MLV
(GP) pseudovirus and lysed 48 h after transfection. (A) Total GP in cell lysate reacted
against mouse monoclonal antibody 6D8-1-2. (B) The same membrane used in Fig. 3A
was stripped and reacted against a mouse anti-β-actin monoclonal antibody. (C) GP on
cell surface detected by antibody 6D8-1-2 following biotinylation of surface proteins
using membrane impermeable biotin reagents and puriﬁcation using streptavidin-
coatedmagnetic beads, as described inMaterials andmethods. (D) The samemembrane
used in Fig. 3C was stripped and reacted against a mouse anti-integrin α5 monoclonal
antibody. (E) GP in the crude pseudovirus supernatant.
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cells
To determine whether the decrease in infectivity was due to a
decrease in binding of retroviral vector pseudotypes to susceptible
cells, we evaluated the binding properties of pseudotype vectors
carrying the mutant GPs using ﬂow cytometry. Since our assay isFig. 4. MLV(GP) pseudovirus binding to cells. (A) Testing of the binding assay. Vero or Jurk
supernatant of mock-transfected cells (grey curves), stained with mouse anti-EBOV GP mon
cells, which were positive by YO-PRO-1 iodide staining, were excluded for analysis. (B) Bindi
average geometric mean ﬂuorescence intensity +/− StdEv.different from previously published binding assays for Ebolavirus GP
(Kaletsky et al., 2007; Kuhn et al., 2006), we ﬁrst analyzed binding in
positive control Vero cells and negative control Jurkat cells. Strong
binding of WT GP pseudovirus was detected on susceptible Vero cells,
as measured by an approximately 30-fold shift in mean ﬂuorescence
intensity (MFI). In contrast, only a very small shift inMFI was detected
on Jurkat cells, consistent with previously reported binding assay
results (Kaletsky et al., 2007; Kuhn et al., 2006) (Fig. 4A). We then
evaluated the binding properties of pseudotype vectors carrying the
mutant GPs, and found that F88 mutants bound to Vero cells as
efﬁciently as the WT did, with the only exception of pseudoviruses
carrying F88A mutant GP, which showed reduced binding. However,
none of the vectors carrying F159 mutant GPs showed a MFI higher
than background (Fig. 4B). The same results were observed when the
binding assay was repeated at room temperature (data not shown).
However, antibody 12B5-1-1, which binds to a linear epitope in the
mucin domain (Wilson et al., 2000), was able to detect all mutant GPs
on the cell surface, suggesting that the negative binding results for
F159 mutants were truly due to lack of virus binding to cells, not due
to inability of 12B5-1-1 binding to the mutant GPs (Fig. 5).
Impact of F88 and F159 mutations on GP's overall structure
In spite of comparable or slightly lower levels of GP detected on
each of the F159mutants relative toWT or F88mutants, no detectable
bindingwas observed for any of the F159mutants, including those that
were infectious. To test whether this was due to mutation-induced
overall structure change, we probed the structure of mutant GPs with
KZ52, a humanmonoclonal antibody that recognizes a conformational
epitope composed of both GP1 and GP2 (Lee et al., 2008; Maruyama et
al., 1999). As a control, we used 12B5-1-1, an antibody that recognizes
a linear epitope in the mucin domain and is able to detect all the
mutant and WT GPs on the cells from the same transient transfection
(Fig. 5).While KZ52 did not detectmutant GPs F159A or F159H,WTGP
and other mutant GPs tested were all detectable by KZ52 (Fig. 5). Twoat cells were mixed with MLV(WT GP) retroviral vector pseudotype (dark curves) or
oclonal antibody 12B5-1-1 (linear epitope) at 4 °C, and analyzed on FACSCalibur. Dead
ng of pseudovirus carrying WT or mutant GP to Vero cells detected by FACS. Shown was
Fig. 5. Monoclonal antibody reactivity with Vero cells transiently expressing WT or mutant GP. COS7 cells were transiently transfected as described in Materials and methods to
express WT or mutant GP (dark curves) and then incubated with anti-EBOV GP monoclonal antibodies (KZ52 or 12B5-1-1), Alexa647-anti-mouse/human IgG, and analyzed on
FACSCalibur. Dead cells, which were positive by YO-PRO-1 iodide staining, were excluded for analysis. Untransfected control cells (grey curves) were stained and analyzed in the
same way.
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samples because the transfection efﬁciency was not 100%. Additional
antibodies that recognize conformational epitopes, 6D3-1-1 and 13C6-
1-1, were able to detect all GPs tested, including those not detected by
KZ52 (data not shown).
Impact of F88 and F159 mutations on GP processing by thermolysin
Following endocytosis, EBOV GP1 must be proteolytically pro-
cessed by cathepsins L and B to a fragment of approximately 19 kDa
before the membrane fusion machinery in GP2 can be released to
induce viral and endosomal membrane fusion (Chandran et al., 2005;
Schornberg et al., 2006). In vitro processing of GP by thermolysin,
which functions at neutral pH, also generates the same fragment and
can be used as a surrogate for cathepsin processing (Dube et al., 2009;
Schornberg et al., 2006). To ﬁnd out whether the structural changes in
F159 mutants would alter the thermolysin processing in vitro, we
treated retroviral vector pseudotypes with thermolysin and analyzed
the processing products by Western blot analysis. The result showed
that there was no WT GP left after 10 min of treatment with
thermolysin (Figs. 6A and B), the ﬁnal 19 kDa fragment increased over
time while the intermediate product (∼44 kDa) decreased (Figs. 6B
and C). The same pattern was observed for F88 mutants, but not F159
mutants, which showed no detectable GP at all after thermolysin
processing, suggesting the F159 mutants were totally digested bythermolysin (Fig. 6). The weak band of approximately 19 kDa
detected for F159 mutants in Figs. 6B and C was background, not GP
processing product, because it was detected in the mock control as
well.
Discussion
In this study, we characterized the structural and functional
impact of the F88 and F159 residues in GP1 by mutating each
phenylalanine to histidine, valine, or tyrosine, respectively. As
summarized in Table 2, infectivity of retroviral vector pseudotypes
carrying the mutant GPs was negatively impacted when the F88 or
F159 residues were mutated to alanine (consistent with our prior
report) or histidine. The reduced infectivity did not correlate with any
change in GP expression or incorporation in viral particles, indicating
the mutations impacted viral entry. For F159 mutant GPs, their
patterns of binding to Vero cells, reactivity to monoclonal antibodies,
and proteolytic digestion by thermolysin were different from those of
WT and F88 mutants, suggesting that the F159 residue plays an
important role in overall conformation. Substitution of the hydro-
phobic nonpolar residues at either position 88 or 159 with valine, or
isoleucine (Manicassamy et al., 2005) resulted in vectors that were
functional, demonstrating that the aromatic side chain of phenylal-
anine does not appear to be the critical biochemical attribute for viral
entry with respect to these two residues.
Fig. 6. Proteolytic processing of GP by thermolysin. MLV(GP) pseudovirus supernatant was prepared and then treated with thermolysin for various lengths of time, as described in
Materials andmethods: 0 min (A), 10 min (B), or 40min (C). The processed GP product was detected by rabbit anti-EBOV GP peptide polyclonal antibody (R. F88-2) onWestern blot.
The three membranes were exposed to a same X-ray ﬁlm, so the exposure time is the same.
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infectivity was detected, but at a somewhat lower titer than for
pseudovirus bearing WT GP (Figs. 2 and 4B). Therefore, F159V and
F159Y must be able to bind to susceptible cells. The lack of detection
of these two mutant GPs' binding to host cells may be a result of a
reduced afﬁnity and inability to remain bound during the FACS
staining procedures. In contrast, the binding was tight enough to
cause infection, suggesting EBOV may not need very tight binding for
productive infection to occur.
We performed additional characterization of the impact of the F88
and F159 mutations on overall structure by analyzing the relative
reactivity of the mutants to KZ52 antibody that detects a conforma-
tional epitope at the interface between GP1 and GP2 (Lee et al., 2008).
KZ52 showed similar level of reactivity to the WT or F88 mutant GPs
by FACS analysis of transiently transfected cells, including mutants
that were non-infectious, F88A and F88H, suggesting that these
mutations did not change the conformation of this particular epitope.
In contrast, the F159 A and Hmutants did not bind to KZ52, indicating
the mutation of the F159 residue directly impacted the conformation
of the KZ52 epitope. Finally, the sensitivity to proteolytic digestion by
thermolysin of F159 mutant GPs was increased. The increased
sensitivity for F159 mutants might be due to higher thermolysin to
GP ratio (Fig. 6). However, we do not think it is likely because, for
example, F88A and F159V quantity was comparable, meaning
comparable enzyme to GP ratio, and a strong 19 kDa product band
was detected for F88A, while no such product was detected for F159V.
The weak 19 kDa bands detected for F159 mutants were background
because a band of the same sizewas detected in themock control lane.
Together, these data indicate that F159 is critical for maintaining GP
structure, which determines GP's binding to host cells and proteolytic
processing by cathepsin (Table 2). Moreover, the recently published
GP crystal structure shows that F159 is deeply buried in a hydrophobic
pocket, thus its role in viral entrywould have to be through an indirect
impact on overall conformation rather than a direct impact on GP
binding (Fig. 1).
We demonstrated that both WT and F88 mutant GPs can be
partially processed by thermolysin, generating the 19 kDa fragment,
consistent with previously reported results of other groups (Chandran
et al., 2005; Dube et al., 2009; Schornberg et al., 2006). In previous
studies, GP1 in vitro processing by cathepsin or thermolysin was
performed on VSV(GP) or FIV(GP) lentiviral vector pseudotypes. We
reported for the ﬁrst time that MLV(WT GP) pseudovirion processing
by thermolysin also generated the same 19 kDa fragment, suggesting
the structure of EBOV GP on all these different retroviral vector
pseudotypes are the same. The conformational change caused by F159
mutations may have altered GP's structure and rendered it more
sensitive to thermolysin processing, which could explain why F159mutants were totally digested/destroyed by thermolysin (Fig. 6). Our
results are consistent with an observation made by Brindley et al, who
found that F159A mutant is resistant to cathepsin L and is totally
digested by cathepsin B (Brindley et al., 2007).
We found that F88 mutants were the same as the WT in most of
the examined characteristics, i.e., expression, binding to various
antibodies, and sensitivity to thermolysin processing, and the only
differences were their infectivity and binding to Vero cells. In our
direct binding assay, the binding of F88A to Vero cells was about 32%
of that of the wt, suggesting F88 might be important for binding.
These observations are similar to Brindley et al. (2007) who showed
that a double mutant G87A/F88A inhibited infection of pseudovir-
ions by approximately 55% (Table 2). However, we found that
pseudovirions bearing the F88H mutation that are also non-
infectious showed binding comparable to WT, indicating that binding
may not be the critical role for the F88 residue. Rather, in aggregate,
our data for the F88 series of mutations suggests that F88 may
impact a step in viral entry after cathepsin processing (Fig. 6, Table
2). While we did not analyze how the F88 mutations impact a post-
cathepsin processing step(s), we hypothesize that it may be involved
in one of two ways. One hypothesis is that cathepsin processing may
further expose F88 and generate a new surface for interacting with
an important unknown endosomal factor, and such interaction may
be inhibited by F88 mutations (Fig. 1D). A second hypothesis is that
F88 mutations may impair the function of the nearby GP2 internal
fusion loop (Fig. 1C).
In summary, our study suggests that F159 is a critical amino acid
for maintaining EBOV GP's overall structure that is important for
proteolytic processing by cathepsin, and thereby the impact on viral
infectivity properties is by an indirect mechanism. We also showed
that certain mutations of F88 resulted in a loss of infectivity, without
any other detectable changes in viral binding (F88H), overall
conformation, or thermolysin sensitivity. Therefore, our study
suggests that F88 plays an important role in a step after cathepsin
processing, not in virus binding. Our study also suggests that weak
binding is sufﬁcient for EBOV infection. Together, our ﬁndings along
with those of others provide important clues for deciphering the
detailed entry process of EBOV and for designing antiviral strategies
that may block viral infection.
Materials and methods
Cell culture
HeLa, 293T, COS7 and Vero cells were maintained in Dulbecco's
Modiﬁed Eagle's Medium (DMEM, Lonza, Walkersville, MD) supple-
mented with 10% fetal bovine serum (FBS, HyClone, Logan, UT), 2 mM
Table 1
Oligonucleotides used for site-directed mutagenesis.
Oligo Sequence
F88H-Fa AACTAAAAGATGGGGCCACAGGTCCGGTGTCCCACCAAAGGT
F88H-Rb ACCTTTGGTGGGACACCGGACCTGTGGCCCCATCTTTTAGTT
F88V-F AACTAAAAGATGGGGCGTCAGATCTGGTGTCCCACCAAAGGT
F88V-R ACCTTTGGTGGGACACCAGATCTGACGCCCCATCTTTTAGTT
F88Y-F AACTAAAAGATGGGGCTACAGGTCCGGTGTCCCACCAAAGGT
F88Y-R ACCTTTGGTGGGACACCGGACCTGTAGCCCCATCTTTTAGTT
F159H-F TGCCTTCCATAAAGAGGGTGCTCACTTCCTGTATGATCGACTTG
F159H-R CAAGTCGATCATACAGGAAGTGAGCACCCTCTTTATGGAAGGCA
F159V-F TGCCTTCCATAAAGAGGGTGCTGTCTTCCTGTATGATCGACTTG
F159V-R CAAGTCGATCATACAGGAAGACAGCACCCTCTTTATGGAAGGCA
F159Y-F TGCCTTCCATAAAGAGGGTGCTTACTTCCTGTATGATCGACTTG
F159Y-R CAAGTCGATCATACAGGAAGTAAGCACCCTCTTTATGGAAGGCA
Note. The underlined sequences encode the mutant amino acids.
a F, forward primer.
b R, reverse primer.
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Jurkat cells were maintained in RPMI (Lonza) with 10% fetal bovine
serum, 2 mM glutamine, 100 U/mL penicillin, and 100 μg/mL
streptomycin (Lonza). Cell cultureswere grown at 37 °C in a humidiﬁed
5% CO2 incubator.
Antibodies
Mouse anti-EBOV GP monoclonal antibodies 6D3-1-1, 6D8-1-2,
12B5-1-1 and 13C6-1-1 were kindly provided by Dr. Gene Olinger at
USAMRIID, Frederick, MD (Wilson et al., 2000). Human anti-EBOV GP
monoclonal antibody KZ52 was kindly provided by Dr. Dennis Burton
at the Scripps Research Institute, La Jolla, CA (Maruyama et al., 1999).
Rabbit polyclonal antibody R.F88-2 was derived by immunizing
rabbits four times with a KLH-conjugated peptide of Zaire EBOV GP
(aa72–109). The sera were collected two weeks after the last
immunization. The peptide was synthesized by NeoMPS (San Diego,
CA) and injected by Epitomics (Burlingame, CA). Anti-Rauscher MLV
P30 goat antiserum was obtained from ATCC (Manassas, VA). Anti-
integrin 5α was from BD Biosciences (San Jose, CA). Anti-β-actin wasTable 2
Summary of phenotypes of EBOV GP mutants.
Present study
Mutation wt F88
A H V
Infectivity (%) 100 0 0.3 66
GP in virionsa + + + +
Binding to Vero (%)b 100 32 101 83
Binding to KZ52b + + + +
Binding to 12B5-1-1b + + + +
19 kDa productc + + + +
Effects on GP functionsd N/A III III III
Brindley et al. Man
Mutation F88e F159 F88
A A L A
Infectivity (%) 0 0 100 1
GP in virionsa + + N/A +
Infection competition(%) 45 39.8 N/A N/A
19 kDa Product Productf + − N/A N/A
Effects on GP functiond I IV N/A N/A
N/A: not analyzed or not applicable.
a Detected by Western blot.
b Detected by FACS.
c Processed by thermolysin.
d I, binding; II, cathepsin processing; III, post cathepsin processing; IV, conformation or p
e Analyzed as part of a double mutant, F88A and G87A.
f Processed by cathepsin B and L.from Sigma (St. Louis, MO). Horse radish peroxidase (HRP)-conju-
gated goat anti-mouse IgG and anti-rabbit IgG antibodies were
obtained from Pierce (Rockford, IL).
Site-directed mutagenesis
The pVR1012-ZEBOV-GP plasmid that encodes the GP of the WT
Zaire EBOV was kindly provided by Dr. Gary Nabel (Vaccine Research
Center, NIH, Bethesda, MD) and Dr. Anthony Sanchez (Centers for
Disease Control and Prevention, Atlanta, GA). The pVR1012-ZEBOV-
GP plasmid was used as the template to generate F88H, F88V, F88Y,
F159H, F159V, and F159Y mutants using the QuickChange II XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) following the
manufacturer's instructions. The complimentary oligonucleotides
(Table 1) containing the intended mutations were ordered from
Integrated DNA Technologies, Inc. (Coralville, IA). The sequence of
each mutant was conﬁrmed by the ABI Prism 3100 Sequence
Detection System using the BigDye® Terminator v1.1 Cycle Sequenc-
ing Kit (Applied Biosystems, Foster City, CA). Mutants F88A and F159A
were described previously (Mpanju et al., 2006).
Generation of retroviral vector pseudotypes
To generate retroviral vector pseudotypes bearing Zaire EBOV GP
(MLV(GP)), 293T cells were seeded in 100 mm cell culture dishes at
a density of 5×106 cells/dish and transfected 24 h later with 60 μL
Lipofectamine 2000 /dish (Invitrogen, Carlsbad, CA) and three
plasmids: 7 μg pVR1012-ZEBOV-GP (WT or mutant), 3.5 μg pMLV-
GagPol, and 14 μg of pRT43.2Tnlsβgal that encodes a Moloney
murine leukemia virus (MoMuLV)-based packageable genome
containing the packaging signal and sequences encoding β-galacto-
sidase with a nuclear localization signal (Finer et al., 1994). Forty-
eight hours after transfection, the culture supernatant, which
contains the retroviral vector pseudotypes, was ﬁltered through
0.45 μm ﬁlter (Millipore), aliquoted, and frozen on dry ice and then
transferred to a −80 °C freezer for storage until needed. The cell
lysate was harvested for Western blot (as described below). The
resulting pseudotypes are composed of a MLV core surrounded byF159
Y A H V Y
93 0 0 28 25
+ + + + +
79 5 4 7 8
+ − − + +
+ + + + +
+ − − − −
III I, II, IV I, II, IV I, II I, II
icassamy et al.
F159
I E A
104 0 1
+ +/− +
N/A N/A N/A
N/A N/A N/A
None IV IV
rotein expression/incorporation into virion.
141W. Ou et al. / Virology 396 (2010) 135–142EBOV GP on the surface and a retroviral genome encoding the lacZ
reporter gene (Table 2).
Viral infectivity assay
One day prior to infection, HeLa cells were seeded in 12-well cell
culture plates at a density of 70,000 cells/well. On the day of infection,
the culture medium was removed and replaced with 1 mL of vector-
containing supernatant that was supplemented with 8 μg/ml
polybrene (American Bioanalytical, Natick, MA). Forty-eight hours
after exposure to vector-containing supernatant, cells were washed
twice with PBS, ﬁxed, and histochemically stained for β-galactosidase
activity. Virus titer was determined by counting the blue forming
units (BFU) as determined by microscopic examination, as previously
described (Wilson and Eiden, 1991).
Western blot analysis
Western blot analysis was performed for both cell lysate and cell
surface proteins. To prepare the cell lysate, 293T cells that were
transfected to generate retroviral vector pseudotypes as described
above were washed once with PBS, detached by gently striking the
dishes, transferred to 5 ml tubes, centrifuged for 5 min at 400×g.
Pelleted material was frozen on dry ice, thawed and lysed for 30 min
on regular ice in lysis buffer: RIPA buffer (150 mM NaCl, 1% (v/v)
Triton X-100, 0.5% (w/v) NaDOC, 0.1% (w/v) SDS, 50 mM Tris
pH 8.0) supplemented with the Complete Mini protease inhibitor
cocktail (1 tablet/7 mL, Roche Applied Science, Indianapolis, IN). The
lysate was cleared by centrifugation for 10 min at 13,000 rpm at 4 °C
in a bench top microcentrifuge. To prepare cell surface proteins, a
second set of 293T cells that were transfected in the same way as
described above were washed once with PBS, resuspended in PBS
supplemented with 1 mg/mL membrane impermeable EZ-Link
Sulfo-NHS-LC-LC-Biotin (Pierce), and incubated for 1 h on ice to
biotinylate cell surface proteins. After biotinylation, the cells were
washed once with PBS supplemented with 100 mM glycine (Sigma)
to quench the excess biotin reagent, washed one more time with
plain PBS, and lysed using the same lysis buffer and conditions as
described above. Streptavidin-coated magnetic beads (MyOne
Streptavidin T1, Invitrogen) were mixed on a bench-top rotator
with pre-cleared lysate from the biotinylated cells for 1 h at room
temperature to capture the biotinylated cell surface proteins. To
wash the beads, the supernatant was removed while the beads were
captured by Dynal MPC-S magnet (Invitrogen), then the beads were
resuspended in 1 ml cold RIPA buffer and rotated for 5 min at room
temperature. In total, four washes were performed. The biotinylated
proteins were eluted by boiling the beads in 1× NuPAGE LDS Sample
Buffer (Invitrogen) for 5 min, resolved on a pre-cast NuPAGE 4–12%
Bis-Tris Gel (Invitrogen), and transferred to PVDF membrane
(Invitrogen) to do Western blot analysis. The membrane was blotted
with one of the following primary antibodies: 6D8-1-2 diluted at
1:10,000, anti-integrin α5 at 1:5000, anti-actin at 1:5000, or anti-
P30 at 1:10,000, then blotted with horse radish peroxidase (HRP)-
conjugated secondary antibodies diluted at 1:10,000, and ﬁnally
developed using the Western Lightning™ Plus Chemiluminescence
Reagent (PerkinElmer, Waltham, MA) following the manufacture's
instructions.
Virus binding assay
Vero cells in T75 ﬂasks (BD, Franklin Lakes, NJ) at a density of 80%
conﬂuency were washed twice with PBS, detached in PBS supple-
mented with 5 mM EDTA, and incubated with 3 mL vector-containing
supernatant for 90min on a rotator at 4 °C to allow the virus to bind to
the cells (106cells/sample). Then the cells were washed once with
3mL FACSWash Buffer (PBS supplemented with 2.5% FBS and 2.5 mMEDTA), then stained for 90 min at 4 °C with the primary antibody
12B5-1-1 diluted at 1:100 in 200 μL FACS Staining Buffer: Invitrogen's
CO2-Independent Medium supplemented with 2.5% FBS and 2.5 mM
EDTA. Following one wash with the FACS Wash Buffer, the cells were
stained for 60 min at 4 °C with Alexa647-conjugated anti-mouse IgG
(Invitrogen) diluted at 1:100 in 200 μL FACS Staining Buffer, washed
twice with 3 mL FACSWash Buffer, resuspended in 500 μL FACSWash
Buffer supplemented with 0.1 μL cell viability dye YO-PRO-1 iodide
(Invitrogen), and immediately analyzed by FACSCalibur (BD Bios-
ciences). Jurkat cells were cultured in suspension, stained and
analyzed in the same manner as for Vero cells.
Flow cytometry analysis
COS7 cells were seeded in 100 mm cell culture dishes at a
density of 3×106 cells/dish and transfected 24 h later with 12 μg
pVR1012-ZEBOV-GP or mutated derivatives described above, and
30 μL Lipofectamine 2000 per dish. Thirty-six hours after
transfection, the cells were washed twice with PBS, detached in
PBS supplemented with 5 mM EDTA, and incubated for 90 min at
4 °C with one of the following primary antibodies: 6D3-1-1, 12B5-
1-1, 13C6-1-1 (1:100) or KZ52 (1:200) diluted in 200 μL FACS
Staining Buffer. Following one wash with 3 mL FACS Wash Buffer,
the cells were incubated for 60 min at 4 °C with Alexa647-
conjugated anti-mouse IgG (Invitrogen) (for cells incubated with
6D3-1-1, 12B5-1-1, 13C6-1-1) or Alexa647-conjugated anti-human
IgG (Invitrogen) (for cells incubated with KZ52) diluted at 1:100 in
200 μL FACS Staining Buffer, washed twice with 3 mL FACS Wash
Buffer, resuspended in 500 μL FACS Wash Buffer supplemented
with 0.1 μL cell viability dye YO-PRO-1 iodide (Invitrogen), and
immediately analyzed by FACSCalibur. Dead cells were excluded by
YO-PRO-1 iodide staining. FlowJo (Tree Star, Ashland, OR) was
used to analyze the data.
Thermolysin processing
Eight-tenths of one milliliter of retroviral vector pseudotype-
containing supernatant was mixed with 15 mL HM reaction buffer
(20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid), 20 mM MES (2-(N-morpholino) ethanesulfonic acid), 130 mM
NaCl, pH 7.5), then centrifuged through 100 kDa Amicon ﬁlters
(Millipore, Billerica, MA) for 15min at 3000×g, and 300 μL virus in HM
buffer was recovered. Thermolysin (Sigma) was prepared by dissol-
ving the powder in HM buffer that was supplemented with 0.2 mM
CaCl2 to a ﬁnal concentration of 0.5 mg/mL. The buffer-exchanged
supernatants were mixed with equal volume of thermolysin and
incubated at 37 °C for 0, 10 or 40 min. The reaction was stopped by
adding 4× NuPAGE LDS Sample Buffer (Invitrogen) to a ﬁnal
concentration of 1× and boiled for 5 min at 99 °C. The processed
and un-processed GP on retroviral vector pseudotypes were resolved
on NuPAGE 4–12% Bis-Tris Gels (Invitrogen) and detected byWestern
blot using R.F88-2 (1:10,000) as the primary antibody, HRP-conju-
gated anti-rabbit IgG (1:10,000) as the secondary antibody, and
Western Lightning™ Plus Chemiluminescence Reagent (PerkinElmer)
as the substrate.
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